Yuxiu Gao1, Ning Shan2, Cheng Zhao1, Yunhai Wang1, Fuliang Xu1, Jiacun Li3, Xiaoqian Yu3, Lifeng Gao3, Zhengjun Yi1. 1. Department of Diagnostic Ultrasound, The Affiliated Hospital of Qingdao University Qingdao, China. 2. Department of Obstetrics, People's Hospital of Rizhao Rizhao, China. 3. Department of Clinical Laboratory, The Affiliated Hospital of Weifang Medical Colloge Weifang, China.
Abstract
BACKGROUND AND OBJECTIVE: Ovarian cancer is among the most lethal of all malignancies in women. While chemotherapy is the preferred treatment modality, chemoresistance severely limits treatment success. Because transforming growth factor-beta (TGF-β) could increase survival of ovarian cancer cells in the presence of cisplatin, we conducted a preclinical study of the antitumor effects of the TGF-β type I (TβRI) and type II (TβRII) kinase inhibitor LY2109761 in combination with cisplatin. METHODS: SKOV3, OV-90 and SKOV3(DDP) cells were treated with LY2109761, and/or cisplatin, and cell viability, apoptosis mRNA and protein expression levels were then evaluated. Furthermore, the efficacy of LY2109761 combined with cisplatin was further examined in established xenograft models. RESULTS: LY2109761 was sufficient to induce spontaneous apoptosis of ovarian cancer cells. Combination with LY2109761 significantly augmented the cytotoxicity of cisplatin in both parental and cisplatin resistant ovarian cancer cells. LY2109761 significantly increased apoptotic cell death in cisplatin-resistant cells. Combination treatment of LY2109761 and cisplatin showed antiproliferative effects and induced a greater rate of apoptosis than the sum of the single-treatment rates and promoted tumor regression in established parental and cisplatin resistant ovarian cancer xenograft models. CONCLUSIONS: Chemotherapeutic approaches using LY2109761 might enhance the treatment benefit of the cisplatin in the treatment of ovarian cancer patients.
BACKGROUND AND OBJECTIVE:Ovarian cancer is among the most lethal of all malignancies in women. While chemotherapy is the preferred treatment modality, chemoresistance severely limits treatment success. Because transforming growth factor-beta (TGF-β) could increase survival of ovarian cancer cells in the presence of cisplatin, we conducted a preclinical study of the antitumor effects of the TGF-β type I (TβRI) and type II (TβRII) kinase inhibitor LY2109761 in combination with cisplatin. METHODS: SKOV3, OV-90 and SKOV3(DDP) cells were treated with LY2109761, and/or cisplatin, and cell viability, apoptosis mRNA and protein expression levels were then evaluated. Furthermore, the efficacy of LY2109761 combined with cisplatin was further examined in established xenograft models. RESULTS:LY2109761 was sufficient to induce spontaneous apoptosis of ovarian cancer cells. Combination with LY2109761 significantly augmented the cytotoxicity of cisplatin in both parental and cisplatin resistant ovarian cancer cells. LY2109761 significantly increased apoptotic cell death in cisplatin-resistant cells. Combination treatment of LY2109761 and cisplatin showed antiproliferative effects and induced a greater rate of apoptosis than the sum of the single-treatment rates and promoted tumor regression in established parental and cisplatin resistant ovarian cancer xenograft models. CONCLUSIONS: Chemotherapeutic approaches using LY2109761 might enhance the treatment benefit of the cisplatin in the treatment of ovarian cancerpatients.
Authors: Paula Fernanda Vázquez; María José Carlini; María Cecilia Daroqui; Lucas Colombo; Mercedes Liliana Dalurzo; David Eduardo Smith; Julieta Grasselli; María Guadalupe Pallotta; Marcelo Ehrlich; Elisa Dora Bal de Kier Joffé; Lydia Puricelli Journal: Clin Exp Metastasis Date: 2013-07-06 Impact factor: 5.150
Authors: Davide Melisi; Satoshi Ishiyama; Guido M Sclabas; Jason B Fleming; Qianghua Xia; Giampaolo Tortora; James L Abbruzzese; Paul J Chiao Journal: Mol Cancer Ther Date: 2008-04 Impact factor: 6.261
Authors: Qiang Zhang; Lin Chen; Brian T Helfand; Thomas L Jang; Vidit Sharma; James Kozlowski; Timothy Michael Kuzel; Lihua J Zhu; Ximing J Yang; Borko Javonovic; Yinglu Guo; Scott Lonning; Jay Harper; Beverly A Teicher; Charles Brendler; Nengwang Yu; William J Catalona; Chung Lee Journal: PLoS One Date: 2011-09-30 Impact factor: 3.240
Authors: Emmanuel Rosas; Justin T Roberts; Kathleen I O'Neill; Jessica L Christenson; Michelle M Williams; Toru Hanamura; Nicole S Spoelstra; Jeffery M Vahrenkamp; Jason Gertz; Jennifer K Richer Journal: Endocrinology Date: 2021-02-01 Impact factor: 4.736
Authors: Elisabeth G D Stribos; Marc A Seelen; Harry van Goor; Peter Olinga; Henricus A M Mutsaers Journal: Front Physiol Date: 2017-12-12 Impact factor: 4.566